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Key points 
What is already known about the topic? 
 Treatments for substance use disorders aim at improving health and, most importantly, 
broader wellbeing. 
 Health-related measures of quality of life may not adequately capture the broader wellbeing 
benefits associated with such complex interventions.  
 Comprehensive evidence on the validity and responsiveness of these measures in this context 
is lacking. 
 When broader capability-wellbeing benefits are expected, NICE recommends the parallel use 
of an ICECAP measure but their measurement properties in this context are yet unknown. 
What does the paper add to existing knowledge? 
 This is the first study exploring the psychometric properties of the EQ-5D-5L and ICECAP-A 
measures in the context of drug addiction. 
 The results indicate that the ICECAP-A is a promising measure for capturing both health and 
broader wellbeing benefits in this context. 
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ABSTRACT 
 
Background:  Measuring outcomes in economic evaluations of social care interventions is 
challenging, as both health and wellbeing benefits are evident.  The ICEpop CAPability instrument 
for Adults (ICECAP-A) and the five-level EuroQol-5D (EQ-5D-5L) are measures potentially suitable 
for the economic evaluation of treatments for substance use disorders.  However, evidence for their 
validity in this context is lacking.  Objective:  To assess the construct validity of the ICECAP-A and 
EQ-5D-5L, in terms of convergent and discriminative validity, and sensitivity to change based on 
standard clinical measures (CORE-OM, TOP, ISEL, LDQ, and SSQ).  Methods:  Secondary analysis 
of pilot trial data for heroin users in opiate substitution treatment.  Baseline convergence with clinical 
measures was assessed using Pearson's correlation coefficient.  Discriminative validity was assessed 
using one-way ANOVA and stepwise regressions.  Sensitivity to changes in clinical indicators were 
assessed at 3 and 12 months using the standardised response mean statistic, and parametric and non-
parametric testing.  Results:  Both measures had the same level of construct validity, except for 
clinical indicators of wellbeing, where the ICECAP-A performed better.  The ICECAP-A was 
sensitive to changes in both health and wellbeing indicators.  The EQ-5D-5L had lower levels of 
sensitivity to change, and a ceiling effect (27%), particularly evident in the dimensions of self-care 
(89%), mobility (75%), and usual activities (72%).  Conclusions:  The findings support the construct 
validity of both measures, but ICECAP-A gives more attention to broader impacts, and is more 
sensitive to change.  The ICECAP-A shows promise in evaluating treatments for substance use 
disorders where recovery is the desired outcome. 
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Introduction 
Generic preference-based measures of health-related quality of life (HrQoL) are well-established in 
the economic evaluation of health care interventions.  Policy makers, such as the National Institute for 
Health and Care Excellence (NICE) in the UK [1], have advocated their use in health technology 
assessment (HTA) as they allow for the direct comparison of cost-effectiveness across interventions 
[2].  Within the UK, the EuroQol-5D (EQ-5D) is the most commonly used preference-based measure 
[3], and the one recommended by NICE for HTA submissions [4].  Since 2011, a five-level version of 
the EQ-5D (EQ-5D-5L) has replaced the previous three-level version (EQ-5D-3L) [5], and emerging 
evidence indicates improved psychometric performance [6-9]. 
The EQ-5D-5L describes HrQoL through dimensions of mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression.  It is designed to measure a core set of domains believed to 
impact on quality of life and linked to health.  However, with this focus on certain aspects of health, 
the EQ-5D may not adequately reflect the impact of all health care interventions [10], such as for 
hearing or vision disorders [11], and severe mental health problems [12], and particularly of those 
resulting in broader personal and interpersonal wellbeing benefits, such as public health and social 
care interventions [13-19].  An alternative framework for measuring treatment benefits is with the 
ICEpop CAPability (ICECAP) measures, underpinned by Amartya Sen’s capability approach [20].  
The ICECAP instruments are designed to measure a particular set of capabilities with less emphasis 
on actual functioning, and more emphasis on the ability to function.  These measures are focused on a 
wider notion of wellbeing and can be used in economic evaluations.  To date, the ICECAP-O (older 
population) [21], ICECAP-A (adult population) [22], and ICECAP-SCM (supportive care) [23]  have 
been developed.  
Opiates carry the highest burden of disease of any drug of dependence, and are a major cause of 
public health problems [24].  In an era of austerity coupled with increasing health care costs, it is 
important that cost-utility analyses are available to guide any evaluation of treatments for opiate use 
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disorders.  One of the challenges of cost-effectiveness analyses in services for substance use disorders 
is that they are intended primarily for single outcome treatments, but substance use disorder treatment 
results in a variety of outcomes [25].  Purchasers of treatment services are increasingly asking “to 
what extent is your service making peoples’ lives better, rather than simply suppressing their drug 
use?” [26, 27], and the process of ‘Recovery’ incorporates not just control over drug use, but also 
physical and mental health, and participating in meaningful roles within society [28-30].   
In such a context, there is need to capture broader aspects of wellbeing than health status [26], and 
NICE recommends a parallel use of the EQ-5D and ICECAP measures [31].  Despite the positive 
emerging evidence for the psychometric properties of the ICECAP-A [32-35] and EQ-5D-5L [6-9], 
no evidence is yet available for the context of opiate dependence.  Even though some supporting 
evidence for the EQ-5D-3L and other similar health-focused measures exists for this context [36-39], 
such measures are used with caution in economic evaluations [40, 41].  This study aims to explore the 
psychometric performance of the ICECAP-A and EQ-5D-5L in a sample of heroin users in opiate 
substitution treatment. 
Methods 
Data source 
The study relies on a secondary analysis of data drawn from a pilot randomised controlled trial 
designed to investigate the clinical and cost-effectiveness of two psychological interventions delivered 
as an adjunct to usual care of individuals who had been receiving opiate substitution treatment for 
more than 12 months.  The full trial protocol can be found elsewhere [42].  The two psychological 
interventions were a brief adapted version of ‘Social Behaviour and Network Therapy (B-SBNT)’, 
which actively aimed to involve social network members in the process of helping participants 
achieve their personal goals [43, 44], and ‘Personal Goal Setting’, which set specific goals and 
monitored achievement on an individual basis [45].  Patients were recruited if they were receiving 
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opiate substitution treatment with methadone or buprenorphine for at least a year but still reported 
heroin use within the past month.  Individuals with concurrent severe mental or physical illness, 
depression, or legal problems were excluded.  Interventions were delivered by three NHS specialist 
drug treatment services in England and participants were followed-up for 1 year.  Participants 
provided written informed consent and ethical approval was granted by the Black Country NHS 
Research Ethics Committee (Reference: 12/WM/0046). 
Outcome measures 
Participants were assessed in terms of substance use (TOP) [46], mental health (CORE-OM) [47], 
social support (ISEL) [48], substance dependence (LDQ) [49], social satisfaction (SSQ) [50], 
capability-wellbeing (ICECAP-A) [22], and HrQoL (EQ-5D-5L) [5].  Questionnaires were completed 
during face-to-face interviews at baseline, and at 3 months and 12 months post-randomisation.  
Further information about each measure is presented below.  
Treatment Outcomes Profile (TOP) 
The TOP is used for monitoring substance use treatment and records information about substance use, 
injecting risk behaviour, offending, and health and social functioning over the past four weeks [46].  
The latter category includes participants’ subjective rating of psychological and physical health status, 
and overall quality of life on a 0 (poor) to 20 (good) scale.  These dimensions were all included in the 
psychometric analysis. 
Clinical Outcomes in Routine Evaluation – Outcome Measure (CORE-OM) 
The CORE-OM is used to assess mental health problem severity and evaluate the impact of 
psychological interventions [47, 51].  It comprises 34 items grouped into the dimensions of wellbeing, 
symptoms (i.e. anxiety, depression, physical symptoms, and trauma), functioning (i.e. closeness, 
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general and social functioning), and risk (i.e. self-risk and risk to others).  Each item is scored on a 0-4 
scale, whereby a higher score denotes increased severity. 
Interpersonal Support Evaluation List (ISEL) 
The ISEL is used to measure perceived availability of social support in terms of material aid (tangible 
support), presence of people to discuss personal issues (appraisal support), presence of people to be 
favourably compared with (self-esteem support), and presence of people to socialize with (belonging 
support) [48, 52].  Each dimension of support comprises 10 items scored on a 0-3 scale, with higher 
values indicating greater support.  Dimension scores are calculated by summing item responses and 
range from 0 to 30. 
Leeds Dependence Questionnaire (LDQ) 
The LDQ is used to measure dependence on a range of substances [49].  It comprises 10 items and 
each item is scored on a 0-3 scale, with higher scores indicating higher levels of substance 
dependence.  A total score, ranging from 0 to 30, is calculated by summing all items, with the values 
of 10 and 20 representing the cut-off points for moderate and high level of dependence. 
Social Satisfaction Questionnaire (SSQ) 
The SSQ is used to assess satisfaction with the social environment in people with substance use 
disorders [50, 53].  It comprises 8 items scored on a 1-4 scale, with higher scores denoting higher 
level of social satisfaction. An overall index score is calculated by summing the score of all items and 
ranges from 8 to 32. 
ICEpop CAPability measure for Adults (ICECAP-A) 
The ICECAP-A is a measure of capability-wellbeing and captures the capability of individuals to 
function in terms of stability, attachment, autonomy, achievement, and enjoyment [22].  Each attribute 
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is scored on a 1-4 scale, with higher values indicating higher capability.  A capability index score is 
assigned to the 1,024 (45) different response permutations using a scoring algorithm based on 
preferences elicited from a sample of 413 members of the UK general population with the best-worst 
scaling method [54].  Capability index scores range from 0 to 1, depending on whether no capability 
or full capability is reported across all five attributes of the ICECAP-A. 
EuroQol five dimensional and five level questionnaire (EQ-5D-5L) 
The EQ-5D is a measure of HrQoL and captures health status in terms of mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression [3].  The EQ-5D-5L dimensions are scored on a 1-
5 scale, with higher values indicating extreme health problems [5].  The different combinations of 
individual responses are used to generate 3,125 (55) health states.  A health index score is assigned to 
each health state using country-specific value sets. An EQ-5D-5L value set for England has recently 
become available [55].  This value set, herein referred to as “EQ-5D-5L England”, was developed 
based on the time trade-off (TTO) and discrete choice experiment (DCE) methods from a sample of 
996 adult members of the general population.  Health index scores range from -0.281 to 1, with 
negative values representing health states worse than death, 0 representing the ‘dead’ state, and 1 the 
‘full health’ state. Until the publication of this value set, studies published in the UK, and elsewhere, 
on the EQ-5D-5L were relying on a crosswalk health index score calculated using a mapping 
algorithm to the UK general population tariff developed for the EQ-5D-3L based on the TTO method 
alone from a sample of 3,395 members [56, 57].  In this value set, herein referred to as “EQ-5D-3L 
UK crosswalk”, health index scores range from -0.594 to 1, with 26.7% of health states being 
considered worse than death.  In the EQ-5D-5L England, these health states correspond to only 4.9% 
of all health states [55]. 
Analyses 
The analysis involved an assessment of construct validity and sensitivity to change of the ICECAP-A 
and EQ-5D-5L.  Analyses using the EQ-5D-5L relied on the EQ-5D-5L England value set.  For 
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completeness, a supplementary analysis was undertaken using the EQ-5D-3LUK crosswalk value set.  
Given that the aim of the study was to explore actual completions of the questionnaires in order to 
ascertain whether the questionnaires work, no data imputation was performed, and analyses relied on 
available cases.  
Construct validity is the ability of an instrument to measure the construct that it was designed to 
measure.  Two forms of construct validity are convergent and discriminative validity [58].  
Convergent validity assesses whether a measure and other variables or measures of the same or an 
overlapping construct are related to each other as expected [58].  The convergence of the ICECAP-A 
and EQ-5D-5L index scores with the five clinical measures was assessed based on baseline data using 
the Pearson correlation coefficient (r).  Correlations were considered strong if r > 0.5, moderate if  0.3 
≤ r ≤ 0.5, and weak if r < 0.3 [59]. 
Discriminative validity assesses the extent to which a measure is able to distinguish between 
dissimilar constructs [58].  A range of constructs were developed based on the different dimensions of 
the five clinical measures.  Where clinical cut-off points were available, these were used to develop 
constructs.  Alternatively, constructs were developed by splitting the sample into those above and 
below the mean score of the relevant clinical measure.  A univariate analysis using one-way ANOVA 
was initially undertaken to explore discriminative validity based on baseline data.  To avoid potential 
confounding problems associated with univariate analyses, a multivariate analysis was additionally 
carried out using stepwise multiple linear regressions.  Age, gender, marital status, ethnicity, 
educational and employment status, type of accommodation, receiving state benefits, length of opiate 
substitution treatment, length of heroin abstinence, and the intervention-arm were used as model 
covariates if they recorded a p-value of ≤ 0.3. 
Due to the small number of participants achieving clinically important changes in some measures 
[60], and the lack of clinically important thresholds of change for all measures, the analysis focused 
on the assessment of sensitivity to change.  In the assessment of sensitivity to change, the different 
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measures are commonly compared for patient groups expected to have experienced a change in health 
and wellbeing based on an external criterion (anchor) [61].  In this analysis, changes in the ICECAP-
A and EQ-5D-5L index scores were evaluated on the basis of overall changes in the number of days 
of abstinence from heroin and changes in the score of the five clinical measures during the first three 
months of the trial (short-term effect) and during the final nine months of the trial (long-term effect).  
Paired t-tests were initially used to identify significant changes in scores.  The changes were also 
evaluated using the standardized response mean (SRM) effect size statistic calculated as the ratio of 
the mean change of index scores to the standard deviation of the change scores [61].  The values 0.2, 
0.5, and 0.8 were used as thresholds for small, moderate and large SRM effect sizes [62].  T-tests were 
used to identify significant differences between groups.  Alongside parametric testing, non-parametric 
tests were explored.  Finally, floor and ceiling effects were calculated as the proportion of participants 
at the lowest and highest level of capability and health respectively.   
A priori hypotheses on the construct and discriminative validity of the measures are shown in the 
online Tables DS1 and DS2.  Expectations about their sensitivity to change dictated that the ICECAP-
A would be more sensitive to indicators related to broader wellbeing, with EQ-5D-5L being more 
sensitive to changes in physical health (TOP) and symptoms (CORE-OM). 
Results 
The trial recruited 83 participants, with 9 (11%) and 13 (15.6%) participants being lost to follow-up at 
3 and 12 months post-randomisation.  Participants had a mean age of 37 years, and were mostly male 
(86.8%) and single (90.4%).  Most participants were also not in paid employment (80.7%), were 
receiving social security benefits (81.9%), and were in opiate substitution treatment for at least two 
years (79.5%).  Mean capability (ICECAP-A) index score was 0.66 (SD = 0.19) and mean health 
(EQ-5D-5L) index score was 0.81 (SD = 0.20).  More information about the sample characteristics is 
available in the online Table DS3. 
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Construct validity 
The convergence of the ICECAP-A and EQ-5D-5L with the five clinical measures is shown in the 
correlation coefficient matrix of Table 1.  Strong correlations (r = 0.55) were found between the 
ICECAP-A index score and the TOP dimensions of psychological health and overall quality of life.  
The correlation with the TOP dimension of physical health was statistically significant (p < 0.01) and 
in the moderate range.  Strong correlations were also found between the ICECAP-A index score and 
the CORE-OM dimensions of wellbeing, symptoms, and functioning.  The convergence with the risk 
dimension of the CORE-OM was marginally below the strong range (r = -0.48).  Statistically 
significant correlations in the moderate range were found with LDQ (r = -0.48), SSQ (r = 0.43), and 
the ISEL dimensions of appraisal (r = 0.36) and self-esteem (r = 0.30). 
In terms of the convergence between the EQ-5D-5L index score and the three TOP dimensions, a 
strong correlation (r = 0.55) was found with the dimension of psychological health, and a moderate 
correlation with the physical health (r = 0.45) and quality of life (r = 0.34) dimensions.  A strong 
correlation was found between the EQ-5D-5L index score and the CORE-OM symptoms dimension, 
with the remaining correlations between the two measures being in the upper end of the moderate 
range.  A low convergence with the ISEL was evident, as the EQ-5D-5L index score was not 
significantly correlated with the tangible, self-esteem, and belonging dimensions of the measure.   
Moderate to strong correlations were found between the EQ-5D-5L index score and the LDQ (r = -
0.48) and SSQ (r = 0.42) scores.  Using the EQ-5D-5L England value set, correlations with the 
dimensions of the five clinical measures were slightly higher compared with the use of the EQ-5D-3L 
UK crosswalk value set, but of similar strength (online Table DS5A). 
Expected correlations between the generic preference-based measures (ICECAP-A and EQ-5D-5L) 
and the five clinical measures were identified except for correlations involving the belonging 
dimension of the ISEL measure.  The only hypothesised correlation that was not identified related to 
the convergence between the EQ-5D-5L index score and the ISEL self-esteem dimension (r = 0.09). 
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(Please insert Table 1 here) 
Table 2 reports the result of the different analyses on discriminative validity.  The findings for both 
the ICECAP-A and EQ-5D-5L confirmed all a priori hypotheses. However, some differences 
between the two measures need to be highlighted.  Based on the results of the multivariate analysis, 
the ICECAP-A identified significant differences in capability-wellbeing, at the 1% level, across most 
dimensions of the five clinical measures. The only dimensions where differences in capability-
wellbeing were statistically significant at the 5% level were for the dimensions of physical health 
status (TOP), belonging (ISEL), and social satisfaction (SSQ).  For the former dimension, significant 
differences in HrQoL at the 5% level were identified by the EQ-5D-5L. For the latter two dimensions, 
however, differences in HrQoL were not statistically significant.  This was also the case for the ISEL 
dimensions of appraisal and self-esteem.  Using the EQ-5D-3L UK crosswalk value set in the 
supplementary analysis, the measure did not also identify statistically significant differences in the 
TOP dimensions of physical health status and overall quality of life as well as the CORE-OM risk 
dimension (online Table DS5B). 
 (Please insert Table 2 here) 
Sensitivity to change 
There were no participants reporting the lowest level of capability or health across all five attributes 
of the ICECAP-A and EQ-5D-5L measures.  There were, however, 22 (26.5%) participants reporting 
full health across all attributes of the EQ-5D-5L, while only 1 (1.2%) participant reported full 
capability.  As evident in online Tables DS4A,B, the proportion of participants at the highest level of 
capability ranged between 9.6% (stability) and 27.7% (autonomy), and the proportion of participants 
at the highest level of health ranged between 34.9% (anxiety/depression) and 89.2% (self-care).  The 
distribution of the ICECAP-A responses for the 22 participants reporting full health based on the EQ-
5D-5L, indicated that only 13.6%-27.3% of them were in a full capability in any of the five ICECAP-
A attributes (online Table DS4C). 
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Table 3 reports the sensitivity of the ICECAP-A and EQ-5D-5L index scores to changes in the 
number of days of abstinence from heroin, and the five clinical measures from baseline to 3-month 
follow-up.  For participants with improved psychological health, wellbeing, self-esteem, belonging, 
dependence, and social satisfaction scores, changes in the ICECAP-A index score were statistically 
significant at the 1% level, with SRM effect sizes being approximately in the moderate range.  
Significant improvements in the ICECAP-A index score at the 5% level were also evident for those 
with more days of abstinence from heroin, improved physical health, overall quality of life, tangible 
support, and appraisal as well as for those without improved functioning and risk.  For these, SRM 
effect sizes were in the small to moderate range.  Statistically significant changes in the EQ-5D-5L 
score occurred only for those with improved levels of symptoms and social satisfaction (Table 3).  For 
these, SRM effect sizes were moderate, while for most of the remaining improvements SRM effect 
sizes were mainly weak.  
(Please insert Table 3 here) 
Table 4 reports the sensitivity to change of the two measures between the 3 months and 12 months 
follow-up period.  For those reporting improvements in psychological health, overall quality of life, 
functioning, appraisal, and social satisfaction, changes in the ICECAP-A index score were statistically 
significant, with the former being significant at the 1% level, and with SRM statistics ranging from 
small to large.  Apart from these, many other changes were found with small SRM effect sizes.  No 
statistically significant changes in the EQ-5D-5L index score were evident, and only improvements in 
symptoms, functioning, and self-esteem had weak SRM effect sizes.  Statistically significant 
differences in capability-wellbeing were observed between those participants who improved overall 
quality of life, symptoms, functioning, appraisal, and social satisfaction, and those who did not.  No 
significant differences in the EQ-5D-5L index score were found between the two groups.  For both 
follow-up periods of the trial, the sensitivity of the EQ-5D-5L to changes in the dimensions of the 
clinical measures was similar regardless of the value set used (online Tables DS5C and DS5D). 
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(Please insert Table 4 here) 
Discussion 
This paper assessed the measurement properties of the ICECAP-A and EQ-5D-5L in a sample of 
heroin users receiving opiate substitution treatment.  The analysis of construct validity indicated that 
both measures had the same level of convergence with the clinical measures, except when dimensions 
of broader wellbeing were involved, where the ICECAP-A showed a higher level of convergence.  
More specifically, correlations between the two measures and the dimensions of psychological and 
physical health, symptoms, risk, dependence and social satisfaction were of the same magnitude, 
while correlations with the dimensions of overall quality of life, wellbeing, functioning, and social 
support (appraisal and self-esteem) were stronger for the ICECAP-A.   
The analysis of discriminative validity indicated that the ICECAP-A has as good discriminative 
properties as EQ-5D-5L for health-related constructs, and that it is able to capture broader wellbeing 
impacts that are likely to be missed by the EQ-5D-5L.  These impacts were particularly evident in 
terms of the capacity to benefit from having close people to discuss personal issues and to socialise 
with or having personal self-esteem. 
The sensitivity to change analysis explored changes in HrQoL and capability-wellbeing in response to 
changes in a number of different clinical anchors at 3 and 12 months post-randomization.  The results 
of the analysis indicated that for 11 out of the 14 anchors used in the short-term follow-up, 
participants reporting clinical improvements had a statistically significant increase in capability-
wellbeing, while in only 2 anchors there were statistically significant improvements in HrQoL.   
Nevertheless, in 10 out of the 14 anchors the SRM statistic for the EQ-5D-5L was above the lower 
threshold of weak effect sizes (0.2).  Although this may provide some supporting evidence on the 
sensitivity to change for the EQ-5D-5L, the findings from the long-term follow-up indicate low 
sensitivity.  Improvements with at least a small SRM effect size were reported in only 3 out of 14 EQ-
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5D-5L anchors, compared with the same change in 9 anchors with the ICECAP-A. Similarly, while 
participants reporting deteriorations in 1 anchor had at least small SRM for the EQ-5D-5L, at least 
small SRM effect sizes were found in 6 anchors for the ICECAP-A.  The use of the EQ-5D-5L 
England instead of the EQ-5D-3L UK crosswalk value set appears to have slightly improved the 
psychometric performance of the measure.  The EQ-5D-5L England value set led to much higher 
HrQoL estimates and with lower variability.  
Several reasons could potentially explain the psychometric performance of the ICECAP-A and EQ-
5D-5L in this clinical context.  Firstly, the descriptive system of the ICECAP-A incorporates more 
determinants of wellbeing than health status.  This explains why the ICECAP-A showed strong 
psychometric properties, not only in terms of overall quality of life, wellbeing, functioning, social 
support and satisfaction but also in terms of physical and psychological health, and symptoms.  
Secondly, the sensitivity of the EQ-5D-5L was hindered by a ceiling effect.  In the study, 22 (26.5%) 
participants reported full health, with only 1 (1.2%) being in full capability.  The ceiling effect was 
particularly evident in the self-care (89.2%), mobility (74.7%), and usual activities (72.3%) 
dimensions, which raises concerns about their relevance in this context.   
To the best of our knowledge, this is the first study exploring the psychometric properties of the 
ICECAP-A and EQ-5D-5L in the context of substance use disorders.  However, some of the findings 
for the EQ-5D-5L are similar to the ones from other studies on EQ-5D-3L.  Research has shown that 
improvements in participants receiving opiate substitution treatment are commonly evident in the 
dimensions of pain/discomfort (33.2%), anxiety/depression (31.5%), and usual activities (30.3%) 
[36].  These dimensions were also the most responsive in this study with 43.2%, 41.9%, and 32.4% of 
participants reporting improvements in the three dimensions respectively during the first three months 
of the trial.  This is possibly due to the large proportion of participants clustered in the full health 
option in the mobility and self-care dimensions.  Validation work on the EQ-5D-3L in a heroin-
dependent population has indicated that 91.4% and 81.9% of participants reported full health in terms 
of self-care and mobility, with the relevant proportion in the rest of the attributes ranging between 
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51.6% (pain/discomfort) and 62.2% (usual activities) [37].  Considering the large ceiling effect found 
in this study, it appears that the extension of response options to the EQ-5D-3L did little to improve 
the sensitivity of the measure, and possibly that the conceptual attributes of the measure do not 
comprehensively capture important patient outcomes in this context, as has recently been reported for 
the wider mental health context [63]. 
The study targeted participants in opiate substitution treatment who still reported heroin use, as they 
represent a group that might be perceived to have made sub-optimal progress in treatment.  The 
analysis of short- and long-term follow-up data and the use of five clinical measures constitute major 
strengths of this study, which allowed for a comprehensive assessment of the psychometric properties 
of the two measures.  There are, however, a number of limitations worth mentioning.  First, the study 
relied on a relatively modest sample size.  Second, in the absence of a gold-standard measure of 
wellbeing, the psychometric properties of the two measures could only be explored based on 
hypothetically developed constructs from specific demographic or contextual variables and other 
clinical measures.  Third, the analysis explored the sensitivity of the two measures on the basis of 
overall changes in different clinical dimensions and not on the basis of clinically meaningful changes, 
which concerns economic evaluations [61].  Finally, the findings of this study are restricted to the 
treatment of opiate dependent patients, and thus transferability of conclusions requires caution. 
Establishing the psychometric performance of a measure is a continuous process and more research is 
needed to explore how well the ICECAP-A and EQ-5D-5L perform in different social care contexts.  
Comparisons with other capability measures developed for social care (ASCOT) [64] and mental 
health (OxCap-MH) [65] or with other measures of HrQoL will contribute toward gaining further 
understanding of their psychometric properties.  Previous evidence has indicated that a shift from 
HrQoL to capability-wellbeing would prioritise funding for those suffering from depression and other 
severe illnesses [66].  Based on the findings of this study, this is also likely to be the case for the 
context of drug addiction, where treatment objectives extend beyond the improvement of health.  The 
ICECAP-A was found to be at least as sensitive as EQ-5D-5L for health-related clinical indicators and 
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more sensitive for clinical indicators related to broader wellbeing, and therefore its use in economic 
evaluations in this context is recommended.  Due to the role of the EQ-5D in current decision making 
process, both measures should be used in the economic analysis of interventions in the context of 
substance use disorders, in line with NICE’s social care recommendation. 
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